Evidence map›Paper›PMID 36380088›Full record

ArticleScientific reports2022

Lung CCR6

Tsukie Kin Tsukuda, Hiroshi Ohnishi, Minoru Fujimoto, Yu Nakatani, Kazufumi Takamatsu, Tetsuji Naka, Akihito Yokoyama

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. HLA-DRRespiratory research · 2026
    Article
  5. Article
  6. Article
  7. CD4Frontiers in immunology · 2025
    Review
  8. Elevated Proportions of Circulating CXCR5Journal of immunology research · 2024
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Tsukie Kin TsukudaDepartment of Respiratory Medicine and Allergology, Kochi Medical School, Kochi University, Kohasu, Oko-Cho, Nankoku, Kochi, 783-8505, Japan.
Hiroshi OhnishiDepartment of Respiratory Medicine and Allergology, Kochi Medical School, Kochi University, Kohasu, Oko-Cho, Nankoku, Kochi, 783-8505, Japan. honi@kochi-u.ac.jp.
Minoru FujimotoCenter for the Intractable Immune Disease, Kochi Medical School, Kochi University, Nankoku, Japan.
Yu NakataniDepartment of Respiratory Medicine and Allergology, Kochi Medical School, Kochi University, Kohasu, Oko-Cho, Nankoku, Kochi, 783-8505, Japan.
Kazufumi TakamatsuDepartment of Respiratory Medicine and Allergology, Kochi Medical School, Kochi University, Kohasu, Oko-Cho, Nankoku, Kochi, 783-8505, Japan.
Tetsuji NakaCenter for the Intractable Immune Disease, Kochi Medical School, Kochi University, Nankoku, Japan.
Akihito YokoyamaDepartment of Respiratory Medicine and Allergology, Kochi Medical School, Kochi University, Kohasu, Oko-Cho, Nankoku, Kochi, 783-8505, Japan.
Kōchi University · JPIwate Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Progressive fibrosing interstitial lung diseases (PF-ILDs) have a poor prognosis and may be resistant to corticosteroids and/or immunosuppressants, but antifibrotic therapies such as nintedanib and pirfenidone have been shown to slow the deterioration of lung function. The aim of this study was to identify the characteristic cellular profile of bronchoalveolar lavage fluid at diagnostic bronchoscopy for predicting PF-ILDs, defined as fibrotic diseases on chest high-resolution computed tomography with more than a 5% relative decline in the percent predicted value of forced vital capacity (FVC) over 6 months. The proportions of inflammatory cells, CCR6

Indexed as

Idiopathic Pulmonary FibrosisLung Diseases, InterstitialBronchoalveolar Lavage FluidDisease ProgressionFibrosisHumansLungReceptors, CCR6Receptors, CXCR3Th2 CellsVital CapacityCCR6 protein, humanCXCR3 protein, humanReceptors, CCR6Receptors, CXCR3

Identifiers

PMID36380088
PMCPMC9666512
OpenAlexW4309192828

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.